Veeva Systems Inc. (VEEV) Stock: Price, Forecast & Analyst Target
Veeva Systems Inc. (VEEV) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $266.22 (+1.26%), as of the Nov 20, 2026 trading session; market cap $43.1B.
Educational signal · not a buy or sell recommendation · How to read this
Veeva Systems Inc. · VEEV · NYSE · Technology · Software - Application
Research dated 2026-09-12: Veeva Systems supplies cloud software, data, analytics and services exclusively to life sciences companies, spanning drug development, regulatory work, quality, safety and commercial operations. The case depends on whether that industry focus can keep subscription revenue and profit compounding fast enough to support a demanding valuation.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Veeva Systems (VEEV)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a fortress balance sheet and durable growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.
Enterprise value relative to sales is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 4 reports
- Altman Z 20.30 · Piotroski F 5
- ROE 14.4% · ROA 7.6% · current ratio 5.46
Holding back: a rich price
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 91 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional | |
| 92 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $266.22 | |
| Change on the day | +1.26% | |
| 52-week range | $148.05–$325.99 | |
| Market capitalisation | $43.1B | — |
| Price / earnings (trailing) | 46.44 | |
| Shares traded on the day | 1.47M | |
| Beta (volatility vs the S&P 500) | 0.88 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Veeva Systems (VEEV): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Veeva Systems (VEEV), and what does it report?
Short answer · as of
Veeva is not a general application-software vendor with incidental healthcare exposure. Commercial Cloud supports customer engagement, medical communications, commercial data and analytics, while Vault manages content and data across clinical, regulatory, quality, safety and commercial workflows.
Research dated 2026-09-12.
Reported revenue primarily measures subscriptions, with professional services and other work forming the smaller component. That mix makes product adoption and expansion within life sciences more important to the economic model than implementation volume alone.
What do the latest results show for Veeva Systems (VEEV)?
Research dated 2026-09-12.
Revenue, gross profit, operating profit and diluted earnings have all advanced across the latest reporting periods. The annual record shows the same direction over a longer span, while reported revenue and earnings have repeatedly exceeded prevailing estimates.
The operating mechanism is subscription growth across Commercial Cloud and Vault, supplemented by implementation, consulting and managed services. Research spending has continued rising as revenue expands, yet operating profit has also increased, indicating that product investment has not prevented further earnings growth.
Management has said that evidence from additional reporting periods will be incorporated into future guidance. That makes the outlook deliberately dependent on further execution rather than a fully settled forward view.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | Not available | Not available | Not available | Not available |
| Apr 30, 2026 | Not available | Not available | Not available | Not available |
| Jan 31, 2026 | Not available | Not available | Not available | Not available |
| Oct 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jul 2025 | $789M | $200M | $1.19 (diluted) |
| Q3 FY2026 | $811M | $236M | $1.40 (diluted) |
| Q4 FY2026 | $836M | $244M | $1.45 (diluted) |
| Q1 FY2027 | $883M | $261M | $1.57 (diluted) |
What are the financial strengths and risks for Veeva Systems (VEEV)?
Short answer
Cash and short-term investments were $0.00 at the Jul 31, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Veeva combines high gross and operating margins with positive operating cash flow and very light capital spending. Cash and short-term investments greatly exceed debt and total liabilities, leaving substantial capacity to fund product development without relying on external financing.
Cash generation is uneven between reporting periods, so near-term cash-flow comparisons can misrepresent the underlying trajectory. The more consequential operating risk is concentration: Veeva is dedicated to life sciences, so weaker demand across that customer base can affect commercial and development products together.
Valuation is the financial pressure point. Earnings and sales multiples assume continued profitable growth, while the cash balance offsets only part of the market value; slower subscription expansion or weaker operating leverage would therefore matter even without balance-sheet stress.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 46.44 runs well above the Technology sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Veeva Systems (VEEV)?
Short answer · as of
Current published price targets run low $165.00 · high $400.00 · consensus $306.67 · median $310.00 against a quoted price of $266.22 (as of Nov 20, 2026).
Research dated 2026-09-12.
The next earnings release should be read for the pace of sequential revenue growth, the relationship between rising research expense and operating profit, and whether the long run of estimate beats continues. Current consensus implies only modest revenue progression from the latest reported level, while the earnings estimate remains close to the recent result.
Subscription performance matters more than professional-services volume because subscriptions dominate the revenue base. Cash conversion also deserves a longer view than any isolated reporting period, given the pronounced timing swings in operating cash flow.
Future guidance should reveal how management incorporates the additional operating evidence it said was still ahead. Any widening between revenue growth and research or selling costs would help show whether current margin strength is durable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Veeva Systems compare with its peers?
Short answer
Veeva Systems's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Veeva differs from broad cloud-software peers through exclusive life sciences specialization and a product set that follows customers from clinical development through regulatory, quality, safety and commercialization. Commercial applications, industry data and Vault workflows sit within the same vendor relationship rather than being separate horizontal tools.
Professional services support deployment and process change, but subscriptions carry most revenue. The result is a software-led model with margins and capital needs unlike service-heavy life sciences technology providers, alongside customer concentration that broader application vendors do not share.
| Company | Price | Market value | Score |
|---|---|---|---|
| $379.02 Nov 19, 2026 | $126B | 98 5-pillar Nov 18, 2026 | |
| $925.70 Nov 20, 2026 | $58.2B | 96 5-pillar Nov 18, 2026 | |
| $676.21 Nov 20, 2026 | $53.3B | 96 5-pillar Nov 18, 2026 | |
| $103.88 Nov 19, 2026 | $59.7B | 93 5-pillar Nov 18, 2026 | |
| Veeva Systems (VEEV) — this page | $266.22 | $43.1B | 92 |
| $83.82 Nov 19, 2026 | $24.5B | 89 5-pillar Nov 18, 2026 | |
| $272.93 Nov 20, 2026 | $63.1B | 88 5-pillar Nov 18, 2026 | |
| $310.02 Nov 19, 2026 | $82.9B | 83 5-pillar Nov 18, 2026 | |
| $195.63 Nov 19, 2026 | $21.3B | 83 5-pillar Nov 18, 2026 | |
| $243.45 Nov 19, 2026 | $50.9B | 81 5-pillar Nov 18, 2026 | |
| $133.01 Nov 19, 2026 | $33.5B | 80 5-pillar Nov 18, 2026 | |
| $173.36 Nov 19, 2026 | $41.8B | 78 5-pillar Nov 18, 2026 | |
| $304.88 Nov 19, 2026 | $83.7B | 78 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $165.00 – $400.00
- Consensus target
- $306.67
- Median target
- $310.00
Consensus record · Captured .
Measured against a quoted price of $266.22 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 15, 2026
- Transactions
- 77
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 12
- Other transactions
- 65
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VEEV in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Fundsmith | Terry Smith | Q3 2026 | 5.98% | $772.24M | Added +231.2% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0% | $0 | Sold out (was $5.45M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Veeva Systems (VEEV)?
VEEV Technology Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What do Veeva Commercial Cloud and Vault actually sell to life sciences companies?
Commercial Cloud combines customer engagement software, medical and marketing tools, data and analytics. Vault manages content and data for clinical, regulatory, quality, safety and commercial work.
Is Veeva mainly a consulting business or a subscription software business?
Subscriptions dominate revenue, while professional services support implementation, configuration, migration, integration and ongoing administration. Economic performance therefore rests more heavily on the software portfolio than on services volume.
Why can Veeva operating cash flow swing while profit remains strong?
Operating cash flow remains positive but varies sharply between reporting periods, whereas reported profit has progressed more steadily. The pattern makes cash conversion more informative across several periods than in isolation.
What would challenge Veeva’s life sciences specialization?
The same specialization that aligns Commercial Cloud and Vault with regulated industry workflows also concentrates demand within life sciences. A broad slowdown in customer spending could reach commercial, clinical and compliance products within the same portfolio.
What is the VEEV stock price today?
The last price recorded for Veeva Systems Inc. (VEEV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the VEEV price target?
The analyst consensus price target for Veeva Systems Inc. (VEEV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold VEEV
Funds in our ETF coverage that list VEEV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 6.87% | |
| IHF ETF | 3.71% |